mofegiline   Click here for help

GtoPdb Ligand ID: 9754

Synonyms: MDL 72974 | MDL-72,974 | MDL-72974A
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Mofegiline was originally identified as a monoamine oxidase B inhibitor [2-3]. Subsequently it has also been identified as an allylamine type irreversible, mechanism-based inhibitor of SSAO/VAP-1 enzyme activity [1,4]. It has antiinflammatory effects in vitro and in vivo. However mofegiline lacks the selectivity exhibited by more recently developed inhibitors such as PXS-4681A.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 26.02
Molecular weight 197.1
XLogP 2.22
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES NCC(=CF)CCc1ccc(cc1)F
Isomeric SMILES NC/C(=C/F)/CCc1ccc(cc1)F
InChI InChI=1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2/b10-7+
InChI Key VXLBSYHAEKDUSU-JXMROGBWSA-N
References
1. Foot JS, Yow TT, Schilter H, Buson A, Deodhar M, Findlay AD, Guo L, McDonald IA, Turner CI, Zhou W et al.. (2013)
PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo.
J Pharmacol Exp Ther, 347 (2): 365-74. [PMID:23943052]
2. Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S. (1995)
Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial.
Clin Pharmacol Ther, 58 (3): 342-53. [PMID:7554709]
3. Terleckyj IA, Heikkila RE. (1992)
In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72,974A and fluorodeprenyl.
Ann N Y Acad Sci, 648: 365-7. [PMID:1637071]
4. Yu PH, Zuo DM. (1992)
Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species.
Biochem Pharmacol, 43 (2): 307-12. [PMID:1739419]
5. Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG. (1989)
MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.
J Neural Transm Park Dis Dement Sect, 1 (4): 243-54. [PMID:2597310]